Studies of biologic drug efficacy in the rheumatic disorders RA and JIA report increased levels of systemic VDBP and apolipoprotein A-I in successful responders, suggesting a shift toward ‘normal’ macrophage activation levels [35,36]. The gene discussed is APOA1; the disease is juvenile idiopathic arthritis.